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Accelerated onset of cnS prion 
disease in mice co-infected with a 
gastrointestinal helminth pathogen 
during the preclinical phase
David S. Donaldson1*, Barry M. Bradford1, Kathryn J. else2 & neil A. Mabbott1*
prion infections in the central nervous system (cnS) can cause extensive neurodegeneration. Systemic 
inflammation can affect the progression of some neurodegenerative disorders. Therefore, we used 
the gastrointestinal helminth pathogen Trichuris muris to test the hypothesis that a chronic systemic 
inflammatory response to a gastrointestinal infection would similarly affect CNS prion disease 
pathogenesis. Mice were injected with prions directly into the cnS and subsequently orally co-infected 
with T. muris before the onset of clinical signs. We show that co-infection with a low dose of T. muris 
that leads to the development of a chronic T helper cell type 1-polarized systemic immune response 
accelerated the onset of clinical prion disease. in contrast, co-infection with a high dose of T. muris that 
induces a T helper cell type 2-polarized immune response did not affect prion disease pathogenesis. The 
reduced survival times in mice co-infected with a low dose of T. muris on d 105 after CNS prion infection 
coincided with enhanced astrocyte activation in the brain during the preclinical phase. these data aid 
our understanding of how systemic inflammation may augment the progression of neurodegeneration 
in the cnS.
Infections with prions cause chronic neurodegenerative diseases to which there are no effective treatments. 
During prion disease PrPSc (abnormally folded isoforms of the host’s cellular prion protein, PrPC) accumulates 
in affected tissues. The build-up of PrPSc within the brain during prion disease ultimately leads to the develop-
ment of spongiform pathology (vacuolation) and neurodegeneration, and coincides with extensive astrocytic 
and microglial activation in targeted regions1. Infectious prion particles appear to be comprised almost entirely of 
PrPSc, suggesting that prions are infectious proteins2,3. Understanding the factors that affect the risk of developing 
clinical prion disease is important for developing treatments and managing disease risk.
Pathogen infection and systemic inflammation can affect the progression of some neurodegenerative disor-
ders. For example, systemic inflammation has been associated with increased cognitive decline in Alzheimer’s 
disease patients4,5, and enhanced neuropathology in a mouse tauopathy model6. A prospective cohort study has 
similarly proposed that gastrointestinal infections increase the risk of Parkinson’s disease7. A systemic inflam-
matory response to infection with a gastrointestinal helminth pathogen can also enhance brain injury in exper-
imental stroke8. However, in some circumstances the effects of certain helminth infections on the host could 
have a beneficial impact, such as dampening autoimmune responses and disease severity in multiple sclerosis 
patients9,10. A negative correlation between infection with Helicobater pylori seropositivity and susceptibility to 
multiple sclerosis has also been described11.
The commensal gut microbiota may also play a role in the progression of some neurodegenerative disorders. 
For example, gut microbiota induced alterations in the induction of peripheral immune tolerance can modulate 
the development of experimental autoimmune encephalitis in mice12. Furthermore, dysbiosis of the commen-
sal gut microbiota is commonly observed in multiple sclerosis patients and may play a pathological role in the 
initiation and progression of this disease13. Effects of dysbiosis on the production of certain commensal-derived 
metabolites may similarly modulate the neurodegenerative disorder amyotrophic lateral sclerosis14.
1The Roslin Institute & Royal (Dick) School of Veterinary Sciences, University of Edinburgh, Easter Bush, EH25 
9RG, Midlothian, United Kingdom. 2Lydia Becker Institute of Immunology and Inflammation, School of Biological 
Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PL, United 
Kingdom. *email: david.donaldson@roslin.ed.ac.uk; neil.mabbott@roslin.ed.ac.uk
open
2Scientific RepoRtS |         (2020) 10:4554  | https://doi.org/10.1038/s41598-020-61483-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 1. Experimental Design. (A,B) Mice were orally infected with a low dose of T. muris infective eggs 
(~20/mouse) and serum collected 35 d later. (A) Comparison of IFN-γ concentrations in the serum of T. 
muris infected mice and uninfected (uninf.) control mice. Each point represents data from an individual 
mouse (n = 5–6 mice/group). **P < 0.01, Student’s t-test. Horizontal bars, median. (B) Analysis of T. muris 
E/S antigen-specific IgG1 (closed circles) and IgG2c (closed squares) levels in the sera of T. muris infected 
mice. Each point represents the mean OD 405 nm ± SEM, n = 3 mice/group. (C) Experiment design. Cartoon 
shows the relative timings of the individual oral T. muris infections in relation to the ongoing prion infection 
in the CNS. Dpi, d post IC prion infection; green arrows, d on which mice were orally infected with a single 
low dose of T. muris. The green triangles represent the relative magnitude of the T. muris-specific immune 
response, with the peak response occurring by ~35 d and gradually declining afterwards. (D,E) Mice were 
injected IC with ME7 scrapie prions directly into the CNS and 84, 112 and 140 d later brains were collected and 
the neuropathology compared by histopathology. (D) The severity of the spongiform pathology (vacuolation) 
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The microglia are the mononuclear phagocytes of the brain and play important roles in maintaining neu-
ronal homeostasis, removing dying cells and protecting against pathogen infection. These cells can play a 
host-protective role during CNS prion disease by phagocytosing and destroying the prions15,16. However, modifi-
cations to microglial activation status can affect the rate of the development of the neuropathology17,18. For exam-
ple, systemic (intraperitoneal) exposure to bacterial LPS induces a pro-inflammatory microglial phenotype19 that 
exacerbates the neuropathology and accelerates the onset of the clinical signs of prion disease20.
The astrocytes in the brain similarly provide homeostatic support to neurons in the steady state, but undergo 
reactive astrocytosis following brain injury and during neurodegenerative diseases. Reactive astrocytes can be 
divided into two main functional subclasses21. The A1 subclass of reactive astrocytes exhibit neurotoxic features, 
whereas the A2 astrocytes express neurotrophic factors and are considered to be neuroprotective21. Reactive 
astrocytes are also induced in the brain during prion disease, but it is uncertain whether they provide protec-
tion from, or contribute to the neurodegeneration. A study using transgenic mice in which PrPC was exclusively 
expressed in astrocytes has shown that these cells can also support prion replication and this can lead to neu-
ropathology22. A separate in vitro study proposed that reactive astrocytes recruit microglia into brain regions 
infected with prions23. Peripheral LPS exposure can also stimulate the development of neurotoxic reactive A1 
astrocytes21. This raises the possibility that systemic inflammatory mediators may similarly manipulate the acti-
vation phenotype of astrocytes and as a consequence modulate CNS prion disease progression.
Trichuris muris is an extensively characterised natural mouse gastrointestinal helminth pathogen. After 
oral exposure the T. muris infection is entirely restricted to the large intestine where the parasite burrows into 
the epithelium24. The characteristics of the host’s immune response to T. muris infection are influenced by the 
magnitude of the infectious dose used. Oral infection of C57Bl/6J mice with a high dose of infective T. muris 
eggs (~200) induces a protective CD4+ T helper cell type 2 (Th2)-polarized immune response. Conversely, low 
dose T. muris infection (~20 infective eggs) induces a chronic parasite-specific Th1-polarized response that is 
non-protective25–27. A previous study has shown that a systemic T. muris-specific Th1-polarized immune response 
can exacerbate the neuropathology in a murine model of stroke8. We therefore used T. muris to test the hypothesis 
that a systemic inflammatory response to co-infection with a gastrointestinal helminth pathogen would similarly 
affect CNS prion disease pathogenesis. We show that a low dose of T. muris infection accelerates CNS prion dis-
ease and this is associated with earlier astrocyte activation. Data from this study will aid our understanding of the 
important factors that can affect the risk of developing clinical prion disease.
Results
co-infection with a low dose of T. muris accelerates the onset of cnS prion disease. As antici-
pated, oral infection of C57BL/6J mice with a low dose of ~20 T. muris infective eggs stimulated the production 
of elevated levels of IFN-γ (Fig. 1A) and IFN-γ-induced parasite-specific IgG2c in the serum (Fig. 1B)8,25,26. These 
data were consistent with the induction of a chronic parasite–specific Th1-polarised antibody response to low 
dose T. muris infection, that is prevented when IFN-γ is depleted26. To determine whether the host’s response to 
low dose T. muris infection might influence the pathogenesis of an ongoing prion infection in the brain, groups 
of C57BL/6J mice were injected with ME7 scrapie prions directly into the CNS by intracerebral (IC) injection. 
The IC route of prion infection was used here as the timing of the development of the neuropathology has been 
extensively characterised28. This also allowed compartmentalisation of the two pathogen infections to distinct 
niches: T. muris to the large intestine; prions to the CNS. Subsequently, individual groups of these mice were 
orally co-infected with a single low dose of ~20 T. muris infective eggs on one of the following days: d 49, d 77 or 
d 105 post IC injection with prions (Fig. 1C). The parasite infections were timed such that the peak of the par-
asite-driven inflammatory response typically encountered at ~35 d post-T. muris infection8,25,26 would coincide 
with the following pre-clinical phases of the on-going prion infection in the brain (Fig. 1C–E):
•	 84 d after IC prion infection, prior to the onset of detectable neuropathology within the brain (Fig. 1D, open 
squares; Fig. 1E, left-hand panels).
•	 112 d after IC prion infection, around the onset of detectable neuropathology within the brain (Fig. 1D, open 
circles; Fig. 1E, middle panels).
•	 140 d after IC prion infection, when signs of neuropathology (spongiform pathology, PrPd accumulation and 
activation of astrocytes and microglia) are detectable within the brain but just before the onset of observable 
clinical signs of disease (Fig. 1D, closed squares; Fig. 1E, right-hand panels).
As anticipated, the control mice injected with prions alone developed clinical prion disease with a mean sur-
vival time of 178 ± 3 d (median = 177 d; Table 1). Mice co-infected with a low dose of T. muris at 49 or 77 d 
after prion infection also succumbed to clinical prion disease with similar survival times to those infected with 
within each brain was scored on a scale of 1–5 in nine grey matter and three white matter areas: G1, dorsal 
medulla; G2, cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, 
septum; G8, retrosplenial and adjacent motor cortex; G9, cingulate and adjacent motor cortex; W1, inferior and 
middle cerebellar peduncles; W2, decussation of superior cerebellar peduncles; and W3, cerebellar peduncles. 
Each point represents the mean vacuolation score ± SEM, n = 4 mice/group. Scores from mice with terminal 
ME7 prion disease are included for comparison. (E) Histopathological comparison of the spongiform pathology 
(H&E, upper row), PrPd accumulation (brown, second row), reactive astrocytes expressing GFAP (brown, third 
row) and active microglia expressing AIF-1 (brown, bottom row) in the brains of mice at times indicated after 
IC injection with prions. Haematoxylin was used as a nuclear counterstain (blue). n = 4 mice/group.
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prions alone (Table 1). However, a significant reduction in the mean survival time of approximately 12 d was 
observed when the mice were co-infected with a low dose of T. muris at 105 d after prion infection (Table 1, 
mean = 166 ± 3 d, median = 168 d, P < 0.019; Fig. 2A, survival curve, prions alone vs. co-infection with a low 
dose of T. muris at 105 d after prion infection, P < 0.0106, Log-rank [Mantel-Cox] test). The reduced survival 
times in these co-infected mice were not associated with a reduced duration of the clinical phase of prion disease 
(Table 1). Instead, co-infection with T. muris at 105 d after prion infection significantly reduced the mean onset of 
detectable clinical signs by approximately 9 d (low dose T. muris at 105 d, mean clinical onset = 143 ± 2 d; prions 
alone, mean clinical onset = 152 ± 3 d; P < 0.035; Table 1).
Co-infection with a low dose of T. muris did not affect the magnitude of the spongiform pathology in the brain 
at the terminal stage of prion disease, when compared to mice infected with prions alone (Fig. 2B,C upper row). 
Heavy deposits of prion disease-specific PrP (PrPd) were also detected in the brains of mice from each group, and 
co-infection with a low dose of T. muris did not influence their abundance (Fig. 2C). The brains of mice with ter-
minal prion disease also display increased astrocyte and microglial activation. Here, glial fibrillary acidic protein 
(GFAP) immunostaining was used to detect reactive astrocytes, and allograft inflammatory factor-1 (AIF-1, also 
known as Iba1) immunostaining was used to detect microglia. Immunohistochemical (IHC) analysis showed 
extensive astrogliosis and microgliosis in the brains of mice infected with prions alone and in those that were 
co-infected with a low dose T. muris at 105 d after prion infection (Fig. 2C). None of these neuropathological 
signs were detected in the brains of mice infected with T. muris alone as a control (Fig. 2B,C). These data show 
that co-infection with a low dose of T. muris did not affect the magnitude of the neuropathology in the brain 
(spongiform pathology, PrPd accumulation, astrocytosis and microgliosis) in clinically-affected mice.
co-infection with a high dose of T. muris does not influence CNS prion disease pathogene-
sis. Oral infection of C57BL/6J mice with a high dose of ~200 infective T. muris eggs induces the development 
of an acute, protective, Th2-polarised immune response that is associated with high levels of parasite-specific 
IgG1 in the serum (Fig. 3A)8,25–27. We next determined whether the effect of T. muris on CNS prion disease was 
specific to co-infection with helminths or the nature of the immune response to the helminth infection. Mice were 
injected IC with prions and subsequently orally co-infected with a single high dose of ~200 infective T. muris eggs 
on one of three distinct intervals after the prion infection (Fig. 3B). As above, the T. muris infections were timed 
such that the peak Th2-polarized inflammatory response (~21 d post-T. muris infection) would occur before or 
during the development of neuropathology within the brain (Fig. 3B).
All mice co-infected with a high dose of T. muris developed clinical prion disease with survival times equiva-
lent to those infected with prions-alone (Table 1). Co-infection with a high dose of T. muris also did not alter the 
timing of the onset or the duration of the clinical phase of prion disease (Table 1), or the severity of the neuro-
pathology in the brain at the terminal stage of disease (Fig. 3C,D).
These data show that the effects of co-infection with T. muris on CNS prion disease were specific to infection 
with a low dose of infective eggs. This raised the hypothesis that factors specific to the development of a chronic 
parasite–specific Th1-polarised immune response may have accelerated the development of the neuropathology 
during the pre-clinical phase.
Effect of T. muris infection on systemic CCL5 synthesis. An independent study8 has suggested that a 
chronic Th1-polarized inflammatory response after low dose T. muris infection augments ischemic brain injury 
in mice via systemic production of the chemokine CCL5. Our analysis confirmed that CCL5 was significantly 
elevated in the sera of mice infected with a low dose of T. muris, but equally high levels were detected in mice 
Mouse model
T. muris 
dose
Timing of oral T. muris 
infectiona (days)
Mean onset of clinical 
prion disease (days)b
Mean duration of clinical 
prion disease (days)c
Mean survival 
times (days)d
Median survival 
times (days)
Clinical 
diseasee
Prions alone none 152 ± 3 26 ± 2 178 ± 3 177 6/6
Prions + T. muris Low 49 152 ± 1NS
25 ± 2
NS
177 ± 3
NS 179 6/6
Prions + T. muris Low 77 154 ± 4NS
23 ± 5
NS
177 ± 4
NS 180 6/6
Prions + T. muris Low 105 143 ± 2P < 0.035f
22 ± 2
NS
166 ± 3
P < 0.019 168 5/5
Prions + T. muris High 63 157 ± 3NS
27 ± 3
NS
183 ± 3
NS 183 6/6
Prions + T. muris High 91 161 ± 4NS
19 ± 3
NS
180 ± 3
NS 177 6/6
Prions + T. muris High 119 150 ± 3NS
29 ± 2
NS
177 ± 4
NS 177 6/6
Table 1. Effect of co-infection with T. muris on CNS prion disease. aAll mice were injected IC with prions on 
the same day. On the days indicated after prion injection the mice were subsequently orally-infected with either 
a low dose (~20) or high dose (~200) of T. muris infective eggs. bMean d ± SEM after IC injection with prions on 
which the first clinical signs of disease were observed. cMean duration ± SEM from first clinical signs of prion 
disease to development of terminal signs of clinical disease. dMean duration ± SEM from IC injection with 
prions to development of terminal signs of clinical disease. eIncidence = no. animals displaying clinical signs of 
prion disease/no. animals tested. fStatistical differences when compared to mice injected with prions alone were 
compared by one-way ANOVA and Student’s t-test. NS, not significant.
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infected with a high dose of T. muris (Fig. 4). Furthermore, serum CCL5 levels were also elevated in some of the 
mice with clinical prion disease (Fig. 4). These data suggested that factors other than systemic CCL5 expression 
were likely to be responsible for the accelerated onset of CNS prion disease pathogenesis in mice co-infected with 
a low-dose of T. muris.
earlier onset of astrocyte activation in mice co-infected with a low dose of T. muris during the 
pre-clinical phase of prion disease. We next determined whether the earlier onset of clinical signs in mice 
co-infected with a low dose of T. muris at 105 d post prion infection coincided with enhanced neuropathology 
during the pre-clinical phase. Mice were injected IC with prions, co-infected with a low dose of T. muris 105 d 
later, and brains analysed at 140 d post prion infection. Age-matched uninfected mice and those infected with 
prions alone or T. muris alone were used as controls. At 140 d post prion infection, a modest increase in the 
Figure 2. Co-infection with a low dose of T. muris does not affect the development of neuropathology at the 
terminal stage of prion disease. Mice were first injected with ME7 scrapie prions directly into the CNS by IC 
injection. Then, at the times indicated after prion infection the mice were orally co-infected with a low dose of 
T. muris infective eggs (~20/mouse; 5–6 mice/group). (A) Co-infection with a low dose of T. muris at 105 d after 
prion infection significantly reduced the clinical prion disease survival time when compared to mice infected 
with prions alone (P < 0.0106, Log-rank [Mantel-Cox] test). (B) The severity of the spongiform pathology 
(vacuolation) within each brain was scored on a scale of 1–5 in nine grey matter and three white matter areas as 
described in the legend to Fig. 1. Each point represents the mean vacuolation score ± SEM, n = 5–6 mice/group. 
(C) Brains were collected from all mice at the terminal stage of prion disease and the neuropathology compared. 
High levels of spongiform pathology (H&E, upper row), heavy accumulations of PrPd (brown, second row), 
reactive astrocytes expressing GFAP (brown, third row) and active microglia expressing AIF-1 (brown, bottom 
row) were detected in the brains of all the terminally-affected mice. Haematoxylin was used as a nuclear 
counterstain (blue). n = 5–6 mice/group. None of the histopathological signs of prion disease were detected in 
the brains of mice infected with a low dose of T. muris alone.
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Figure 3. Co-infection with a high dose of T. muris does not affect the development of neuropathology at the 
terminal stage of prion disease. (A) Analysis of T. muris E/S antigen-specific IgG1 (closed circles) and IgG2c 
(closed squares) levels in the sera of mice 21 d after high dose T. muris infection (~200 infective eggs). Each 
point represents the mean OD 405 nm ± SEM, n = 3 mice/group. (B) Experiment design. Cartoon shows the 
relative timings of the oral T. muris infections in relation to the ongoing prion infection in the CNS. Dpi, d 
post IC prion infection; green arrows, d on which mice were orally infected with a single high dose of T. muris 
infective eggs. The green triangles represent the relative magnitude of the T. muris-specific immune response, 
with the peak response occurring by ~21 d and gradually declining afterwards. (C) Mice were injected with 
ME7 scrapie prions directly into the CNS by IC injection and subsequently orally infected with a high dose 
of T. muris infective eggs at the times indicated (n = 6 mice/group). Brains were collected from all mice with 
terminal prion disease and the neuropathology compared. High levels of spongiform pathology (H&E, upper 
row), heavy accumulations of PrPd (brown, second row), reactive astrocytes (GFAP+ cells, brown, third row) 
and active microglia (AIF-1+ cells, brown, bottom row) were detected in the brains of all the terminally-
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magnitude of the spongiform pathology was observed in the hippocampus and septum regions (G6 and G7 
regions, respectively) of the brains of mice co-infected with T. muris when compared to mice infected with prions 
alone (Fig. 5A). However, comparison of the magnitude of the AIF-1+ and GFAP+ immunostaining suggested a 
similar abundance of reactive microglia (Fig. 5B,C) and astrocytes (Fig. 5B,D) respectively, in these regions at this 
time after prion infection. Similar levels of PrPd (IHC; Fig. 5B,E) and PrPSc (immunoblot; Fig. 5F,G) accumulation 
were also detected in the brains of mice infected with prions alone and those co-infected with prions and T. muris.
The reactive astrocytes that are induced in the brain after various pathological insults can contribute to the 
neurodegeneration, or aid the recovery of the CNS, dependent upon their subclass. The A1 subclass of reac-
tive astrocytes display neurotoxic properties and can induce neurodegeneration, whereas the A2 astrocytes are 
neurotrophic and can provide neuroprotection21,29,30. Expression of CD44 expression is significantly elevated in 
neurotoxic A1 astrocytes21. We have also shown that CD44, including the CD44v6 isoform, is expressed highly 
in specific astrocyte populations in brain areas associated with pathology during CNS prion disease31. Here, 
low levels of reactive astrocyte-associated CD44 expression were detected in the hippocampus at 140 d post 
infection with prions alone (Fig. 6A,B). However, CD44 expression was significantly higher in the brains of 
mice co-infected with T. muris at 105 d after prion infection (Fig. 6A,C). Significantly higher levels of reactive 
astrocyte-associated CD44v6 isoform expression were also detected in the hippocampus of the co-infected mice 
at this time when compared to mice infected with prions alone (Fig. 6D,E). Expression of mRNA encoding the 
neurotoxic A1 astrocyte markers21 guanylate binding protein 2 (Gbp2), proteasome subunit beta 8 (Psmb8) and 
serglycin (Srgn) was elevated in the brains of mice infected with prions alone at the terminal stage (Fig. 6F–H). 
At d 140 post infection with prions alone there was only modest increase in the expression of these A1 
astrocyte-associated genes (Fig. 6I–K). However, on d 140 in the brains of mice co-infected with prions and T. 
muris the expression of Gbp2, Psmb8 and Srgn was significantly higher when compared to uninfected mice and 
mice infected with prions alone (Fig. 6I–K), suggesting an earlier onset of expression of A1 astrocyte-associated 
genes in the brains of co-infected mice. In contrast, expression of the A2 astrocyte-associated genes B3gnt5, Ptx3, 
Slc10a6 and Tm4sf1 was not upregulated on d 140 in the brains of the co-infected mice above the level observed 
in uninfected mice (Fig. 6L–O). Together, these data suggest that co-infection with a low dose of T. muris during 
the pre-clinical phase of prion disease coincided with the earlier onset of expression of certain markers associated 
with neurotoxic A1 astrocyte activation.
Reactive astrocytes express ifn-γ receptor 1 (IFNGR1) during CNS prion disease. Limited, if 
any, astrocyte-associated IFNGR1 expression was detected in the brains of uninfected mice, or mice infected 
with T. muris alone (Fig. 7A). However, coincident with a Th1-polarised immune response induced by low dose 
T. muris infection, and the shorter prion disease survival times, the reactive GFAP+ astrocytes throughout the 
brains of mice that were co-infected with prions and T. muris also expressed IFNGR1 highly (Fig. 7A). This coin-
cided with significantly elevated levels of IFN-γ in the sera of mice co-infected with prions and T. muris (Fig. 7B). 
Modest but significantly elevated levels of mRNA-encoding IFN-γ (Ifng) were also detected in the brains of mice 
co-infected with prions and T. muris (Fig. 7C), implying that certain cell populations within the CNS of the 
co-infected mice may also be producing this cytokine. Consistent with this hypothesis, IHC analysis detected 
IFN-γ predominantly in association with astrocytes in the brains of the co-infected mice (Fig. 7D,E). Although 
IFNGR1 was also expressed highly in reactive astrocytes in the brains mice infected with prions alone (Fig. 7A), 
IFN-γ expression was undetectable in the sera and brains of these mice (Fig. 7B–E) consistent with previous 
data32.
Chronic T. muris infection is known to stimulate the development of high levels of IFN-γ+ CD8+ T cells 
within the gut draining lymph nodes33, which can accumulate in other sites such as the bone marrow34. Low 
levels of CD8+ T cells have been reported to infiltrate the brains of mice and humans during CNS prion dis-
ease35. Here, few if any CD8α+ cells were detected by IHC in the hippocampus at 140 d post infection with 
prions alone, whereas a significantly increased abundance of CD8α+ cells was detected in the co-infected mice 
(Fig. 8A,B). This coincided with a significant increase in Cd8a (encoding CD8α) mRNA expression in brains 
from the co-infected mice (Fig. 8C). These data suggested that co-infection with T. muris may have stimulated the 
recruitment of CD8+ T cells into the prion disease-affected brain.
Discussion
Systemic inflammation can have a significant impact on the progression of some neurodegenerative disor-
ders4–8,36. Consistent with the suggestion that systemic inflammation may affect CNS prion disease pathogen-
esis20, we show that the onset of clinical prion disease was accelerated in mice co-infected with a low dose of T. 
muris that develop a chronic Th1-polarized systemic immune response. The reduced prion disease survival times 
in mice co-infected with a low dose of T. muris coincided with enhanced astrocyte activation during the preclini-
cal phase, including the earlier onset of expression of certain neurotoxic A1 astrocytes-associated markers. When 
A1 astrocytes are induced they rapidly lose their homeostatic functions and instead gain neurotoxic properties 
that can kill neurons and oligodendrocytes21. This raises the hypothesis that the earlier onset of the reactive 
astrocyte activation in the brains of the co-infected mice may have contributed to the accelerated development of 
affected mice. Haematoxylin was used as a nuclear counterstain (blue). None of the histopathological signs of 
prion disease were detected in the brains of mice infected with a high dose of T. muris alone. (D) The severity 
of the spongiform pathology (vacuolation) within each brain was scored on a scale of 1–5 in nine grey matter 
and three white matter areas as described in the legend to Fig. 1. Each point represents the mean vacuolation 
score ± SEM, n = 6 mice/group.
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clinical prion disease, and suggests that pharmacological modulation of astrocyte phenotype may be beneficial 
during the CNS phase of prion disease.
Co-infection with a high dose of T. muris that induces a protective Th2 polarized immune response did not 
affect prion disease pathogenesis. Thus, our data show that the earlier onset of clinical signs of prion disease and 
reduced survival times were specific to mice with a chronic parasite-specific, IFN-γ-mediated, Th1 polarized 
immune response induced by co-infection with a low dose of T. muris25,26. The effects on prion disease pathogen-
esis observed in the current study are specific to the CNS phase of prion disease, as we have previously shown that 
co-infection with T. muris around the time of oral prion exposure does not affect prion disease pathogenesis37. 
Systemic production of the chemokine CCL5 was previously identified as the critical factor responsible for the 
augmented ischemic brain injury in mice undergoing a similar Th1 polarized immune response to T. muris infec-
tion8. However, we found no correlation between serum CCL5 concentrations and prion disease duration. Since 
prion disease pathogenesis and susceptibility are not affected in the absence of CCR5 (the receptor for CCL5)38, 
our data suggest that factors other than systemic CCL5 expression are responsible for the accelerated CNS prion 
disease pathogenesis in the co-infected mice.
We were unable to identify the precise molecular factor/s responsible for the effect of low dose T. muris infec-
tion on CNS prion disease pathogenesis. However, in support of the observation that this effect was specific to a 
chronic parasite-specific, IFN-γ-mediated Th1 polarized immune response26, we observed that reactive astrocytes 
expressed IFNGR1 highly during CNS prion disease. Stimulation of astrocytes with IFN-γ can induce neurotoxic 
activity39. This raises the hypothesis that IFN-γ-mediated stimulation may have induced the earlier onset of neu-
rotoxic activity in reactive astrocytes in the co-infected mice during the pre-clinical phase of prion disease. An 
independent study has also reported that the expression of several IFN-γ inducible genes is upregulated in the 
brains of mice infected with prions40, and some of these genes are induced in astrocytes by IFN-γ stimulation41. 
Amongst these is the A1-astrocyte-associated gene Gbp2 that we show is also upregulated in the brain during 
prion disease. Expression of proteosomal subunit genes including PSMB8 is also inducible by IFN-γ stimula-
tion42. Our previous pathway analysis also implicated IFN-γ as an upstream regulator during CNS prion disease 
pathogenesis43, and a transcriptomic signature enriched in IFN pathway-associated genes has been observed in 
A1 neurotoxic astrocytes in the aged human brain44. Expression of IFNGR1 mRNA is also specifically upregu-
lated in reactive astrocytes in the hippocampus following entorhinal deafferentation45, and astrocyte-associated 
IFNGR expression has been detected in affected regions of the brains of patients with Alzheimer’s disease, amyo-
trophic lateral sclerosis and Parkinson’s disease39. Although IFN-γ was detected in the sera of mice co-infected 
with prions and T. muris, it was undetectable in mice infected with prions alone, consistent with previous data32. 
This implies that the upregulated expression of IFNGR1 on reactive astrocytes during CNS prion disease primes 
them to respond to subsequent IFN-γ-mediated stimulation.
The majority of astrocytes maintain direct physical contacts with vascular endothelial cells and pericytes via 
their endfeet, and these cells provide trophic support to astrocytes46. Thus, it is plausible that in the brains of mice 
co-infected with prions and T. muris the association of IFNGR1-expressing astrocytes with blood vessels would 
enable them to be directly stimulated by the elevated levels of IFN-γ in the serum. We also detected low levels 
of Ifng expression specifically in the brains of the co-infected mice, and our IHC analysis suggested IFN-γ was 
predominantly associated with astrocytes. This implies either that the astrocytes were producing this cytokine 
themselves in response to the parasite infection and being stimulated by it in an autocrine manner, or conversely 
that they had acquired IFN-γ from other sources.
Future studies using IFNGR1-deficient mice, and/or mice with conditional deficiencies in IFNGR1 or IFN-γ 
in astrocytes are clearly necessary to determine the influence that IFNGR1-mediated signalling has on astrocyte 
Figure 4. Serum CCL5 levels in T. muris infected mice and mice with terminal prion disease. Serum was 
isolated from peripheral blood collected from uninfected mice (uninf.), 21 d after low dose of T. muris infection 
(~20 infective eggs/mouse), 35 d after high dose of T. muris infection (~200 infective eggs) and at the terminal 
stage of prion disease. Each point represents data from an individual mouse, n = 6–8 mice/group. Horizontal 
line, median. *P < 0.05, Students t-test.
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Figure 5. Effect of co-infection with a low dose of T. muris on the development of neuropathology during 
the pre-clinical phase of prion disease. Mice were first injected with ME7 scrapie prions directly into the CNS 
by IC injection and 105 d later they were orally co-infected with a low dose of T. muris infective eggs (~20/
mouse). Brains were collected at 140 d after prion infection during the pre-clinical phase of disease and the 
neuropathology compared. (A) The severity and distribution of the spongiform pathology (vacuolation) within 
each brain was scored on a scale of 1–5 in nine grey matter and three white matter areas as described in the 
legend to Fig. 1. Each point represents the mean vacuolation score ± SEM, n = 5–6 mice/group. *P < 0.05, 
Students t-test. (B) Immunohistochemical analysis of PrPd accumulation (brown, upper row), reactive 
astrocytes (GFAP+ cells, brown, middle row) and active microglia (AIF-1+ cells, brown, bottom row) in 
the hippocampus and septum of mice from each group. Haematoxylin was used as a nuclear counterstain 
(blue). (C–E) Morphometric analysis suggested that the area of the (C) AIF-1+, (D) GFAP+ and (E) PrPd+ 
immunostaining in the hippocampus and septum was similar in the brains of mice co-infected with T. muris 
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phenotype and CNS prion disease pathogenesis during the steady state, and in the presence of systemic inflam-
mation. This will also help address whether systemically produced (serum) IFN-γ has the major influence on 
astrocyte phenotype, or whether astrocyte-derived IFN-γ modulates their phenotype in an autocrine manner.
Although low levels of CD4+ and CD8+ T cells have been reported to infiltrate the brains of mice and 
humans during CNS prion disease35, T cells do not contribute to CNS prion disease pathogenesis during the 
steady-state47–49. We detected a significantly increased abundance of CD8α+ cells in the hippocampus of the 
co-infected mice, suggesting that co-infection with T. muris stimulated the recruitment of CD8+ T cells into 
the prion disease-affected brain. Studies using an experimental reovirus-induced encephalitis model show that 
IFN-γ can induce changes in the endothelium of the blood-brain barrier that lead to increased permeability and 
the infiltration of CD3+ and CD8+ T cells into the CNS50. In the current study it is plausible that serum IFN-γ 
produced in response to low dose T. muris similarly affected the integrity of the blood-brain barrier in the of the 
co-infected mice, leading to increased infiltration of CD8+ T cells into the brain. The IFN-γ+ CD8+ T cells 
generated in response to low dose T. muris infection can accumulate in other sites such as the bone marrow34. 
This suggests that in addition to the increased number, the higher proportion of the CD8+ T cells found in the 
brains of co-infected mice may also be expressing IFN-γ. Clonally-expanded CD8+ T cells have been shown to 
enter the cerebrospinal fluid and brains of patients affected with Alzheimer’s disease51. Transcriptional analysis 
showed these cells had enhanced expression of genes encoding pro-inflammatory cytokines, cytotoxic granules 
and proteases, implying a potential role in the neurodegeneration. However, it remains to be determined whether 
CD8+ T cells are also sources of IFN-γ in the CNS, exhibit cytotoxic properties and contribute directly to the 
neurodegeneration in mice co-infected with prions and T. muris.
When the mice were co-infected with a low dose of T. muris on d 49 and d 77 this did not affect the onset of 
prion disease. The peak of the parasite-specific, IFN-γ-mediated, Th1-polarised inflammatory response in these 
instances was timed so that it would occur around d 84 and d 112 post injection with prions, and before the 
development of significant neuropathology (Fig. 1C,D). Data from the analysis of AKR mice that also develop 
a chronic Th1-polarised immune response after T. muris infection52 suggest that the magnitude of the systemic 
IFN-γ response in these mice is likely to have declined significantly by the time the co-infected mice began to 
display detectable clinical signs of prion disease (~152 days in current study). However, when the mice were 
co-infected on d 105, the peak of the IFN-γ response on d 140 was associated with the earlier activation of the 
astrocytes in the brain, and accelerated prion disease. Here, the timing of the T. muris co-infection was selected so 
that the peak of the inflammatory response coincided with the presence of detectable signs of neurodegeneration 
(spongiform pathology/vacuolation) in the CNS at d 140 (Fig. 1D), and just before the onset of clinical signs. 
This suggests that the presence of a strong systemic IFN-γ-mediated, Th1-polarized inflammatory response may 
accelerate CNS prion disease in mice with detectable signs of neurodegeneration. Conversely, a strong systemic 
Th1-polarized inflammatory response is unlikely to influence the onset of CNS prion disease if it occurs much 
earlier during the infection and before the development of the neuropathology.
Widespread dietary exposure of the UK human population to bovine spongiform encephalopathy (BSE) pri-
ons is likely to have occurred during the epidemic in the UK cattle herd in the 1980s53,54. Fortunately however, 
relatively few human cases of variant Creutzfeldt-Jakob disease (vCJD) due to the consumption of BSE con-
taminated food55 have been recorded in the UK (178 definite and probable cases, January 2020)56. However, 
histopathological analyses of PrPd accumulation in archived human appendix and tonsil samples have proposed 
that the incidence of individuals with pre-clinical vCJD infection could be higher57,58. This discrepancy sug-
gests the potential existence of subclinical carriers. Our data show that CNS prion disease was accelerated in 
mice co-infected with a low dose of T. muris during the pre-clinical phase. Whether inflammatory mediators 
produced in response to pathogen co-infections similarly accelerate the progression of CNS prion disease in 
pre-clinically-affected individuals remains to be determined.
Our study addresses an important gap in our understanding of how systemic inflammation in response 
to co-infection with a gastrointestinal pathogen may accelerate CNS prion disease pathogenesis in 
pre-clinically-affected individuals. Expression of IFNGR may also be upregulated in the brains of patients with 
Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease and multiple sclerosis39. Thus, our data 
imply that targeting of the IFN-γ response in the immune system and/or the downstream response in astrocytes 
may have therapeutic value in delaying neurodegenerative disease progression across a range of disorders.
Materials and Methods
ethics statement. Ethical approvals for the in vivo mouse experiments were obtained from The Roslin 
Institute’s and University of Edinburgh’s ethics committees. These experiments were also performed under the 
authority of UK Home Office Project Licences (PPL60/4325 & PA75389E7) in accordance within the guidelines 
and regulations of the UK Home Office ‘Animals (scientific procedures) Act 1986’. Appropriate care was provided 
(open bars), when compared to mice infected with prions alone (closed bars). Data represent mean ± SEM, 
n = 5–6 mice/group, not significantly different to prions alone, Mann-Whitney U test (C) and Student’s t-test 
(D,E). (F) Immunoblot shows similar levels of proteinase (PK) resistant PrPSc in brains of mice from each 
treatment group collected at 140 d after prion infection. Uninf., uninfected (control) mice. Three bands are 
characteristically detected after PK treatment representing the un-glycosylated, mono-glycosylated, and di-
glycosylated isomers of PrPSc. (G) Densitometric comparison of PrPSc detected by immunoblot in brains of mice 
infected with prions alone or co-infected with prions or T. muris. Data are presented as relative % PrP signal in 
uninfected control. n = 6 mice/group, not significantly different, Student’s t-test.
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Figure 6. Earlier onset of astrocyte activation in the brains of mice co-infected a low dose of T. muris during 
the pre-clinical phase of prion disease. Mice were first injected with ME7 scrapie prions directly into the CNS 
by IC injection and 105 d later they were orally co-infected with a low dose of T. muris infective eggs (~20/
mouse). Age matched uninfected mice, and mice infected with prions alone or T. muris alone were used as 
controls. Brains were collected during the pre-clinical phase of disease at 140 d after prion infection. (A) 
Immunohistochemical (IHC) analysis of CD44 expression in the hippocampus of mice from each group. 
Haematoxylin was used as a nuclear counterstain (blue). (B) IHC showed that CD44 (blue/back) was expressed 
in association with GFAP+ astrocytes (red/brown) in the brains of mice infected with prions. (C) Comparison 
of the magnitude of the CD44+ immunostaining (OD, relative optical density) in the hippocampus of mice 
infected with prions alone or co-infected with T. muris at 105 d after prion infection. *P < 0.05, Student’s t-test, 
n = 5–6/group; horizontal bar, median. (D) Immunofluorescence microscopy showed that CD44v6 (green) 
was highly expressed in association with GFAP+ astrocytes (magenta) in the brains of mice co-infected with T. 
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to minimise harm and suffering, and anaesthesia was administered where necessary. Mice were humanely culled 
at the end of the experiments by cervical dislocation.
Mice. This study used six to eight weeks old female C57BL/6J mice (Charles River, Margate, UK), and these 
were maintained under SPF conditions.
prion infection. Mice were injected IC with 20 µl of a 1% (v/w) terminal scrapie brain homogenate, contain-
ing approximately 1 × 104 IC ID50 units of ME7 scrapie prions. The mice were then coded and assessed blindly 
by independent technicians at weekly intervals until they displayed definite clinical signs of prion disease, from 
which time they were assessed at daily intervals and daily culled as described59. The early clinical signs of prion 
disease in mice infected with ME7 scrapie prion can include weight loss, starry coat, hunched posture and jumpy 
behaviour. During the later stages of prion disease the clinical signs may also include hind-limb ataxia, lim-
ited movement and decreased awareness, upright tail, wet genitals, discharge from eyes and/or blinking eyes. 
Following assessment for the above clinical signs of prion disease the mice were scored as “unaffected,” “possibly 
affected,” and “definitely affected”. Mice were culled at the clinical endpoint of disease. This was defined as either 
after two consecutive “definite” ratings, or after a third “definite” rating within four consecutive weeks. Survival 
times were recorded as the duration from day of IC injection with prions to day of cull at the clinical endpoint. 
Histopathological assessment of the magnitude and distribution of the prion disease-specific spongiform pathol-
ogy in the brain was used to confirm the clinical status of each mouse as described28. All the mice presented in 
Table 1 were injected IC with prions on the same day using inoculum derived from the same pool of terminal 
scrapie brain homogenate.
trichuris muris infection. T. muris was maintained as described24. Mice were infected orally by gavage with 
either ~20 (low dose) or ~200 (high dose) infective eggs and worm burdens in the large intestine were determined 
as described60,61. Mean worm burdens at the peak of inflammation following infection with ~20 infective eggs (35 
d) or ~200 infective eggs (21 d) were 2 ± 1 and 20 ± 7, respectively (n = 3–4/group).
T. muris Antigen-specific serum antibody responses. Serum T. muris excretory/secretory (E/S) 
antigen-specific IgG1 and IgG2c concentrations were measured by ELISA as described27,62,63.
chemokine and cytokine quantitation. Serum CCL5 concentrations were determined by using 
either a mouse/rat CCL5/RANTES Quantikine ELISA kit (Bio-techne, Abingdon, UK) or a mouse RANTES 
FlowCytomix Simplex kit (Ebioscience, Paisley, UK), according to the manufacturers’ instructions. Serum IFN-γ 
concentrations were determined using a MILLIPLEX MAP mouse TH17 magnetic bead panel (Merck Millipore, 
Watford, UK) array according to the manufacturer’s instructions.
immunohistochemistry. Brains were fixed in periodate-lysine-paraformaldehyde and then embed-
ded in paraffin wax. To enhance the detection of disease-specific PrP (PrPd) sections (5 µm) were first treated 
with hydrated autoclaving (15 min, 121 °C, hydration) followed by immersion in formic acid (98%) for 5 min. 
Sections were then immunostained with 1B3 PrP-specific polyclonal antiserum64. For all other immunostain-
ings the sections were autoclaved as above in Target Retrieval Solution (DAKO, Ely, UK). GFAP was detected 
using polyclonal rabbit anti-glial fibrillary acidic protein (DAKO). N-terminal (pan-) CD44 was detected using 
biotinylated anti-CD44 (clone IM7; Biolegend, London, UK). The CD44 variant 6 isoform was detected using 
rat anti-mouse CD44v6 (Clone 9A4; eBioscience, Hatfield, UK). CD8+ cells were detected using anti-CD8α 
(D4W2Z) XP rabbit monoclonal antibody (mAb) (Cell signalling Technology, London, UK). IFN-γ was detected 
using anti-IFN-γ mAb (clone XMG1.2; ThermoFisher Scientific, Perth, UK). INFGR1 was detected using biotiny-
lated anti-CD119 (IFN-γ R α chain; clone 2E2; Biolegend). AIF-1+ (also known as Iba1) microglia were detected 
using polyclonal anti-rabbit Iba1 antibody (Wako Chemicals GmbH, Neuss, Germany). For light microscopy, 
appropriate species-specific biotin-conjugated secondary antibodies (Jackson ImmunoResearch Europe Ltd., Ely, 
UK) were then applied followed by HRP-conjugated to the avidin-biotin complex (ABC kit, Vector Laboratories, 
Peterborough, UK). For anti-CD44 and anti-GFAP co-immunostaining, CD44 was detected using the HRP sub-
strate Vector NovaRed (Vector Laboratories) and GFAP detected with alkaline phosphatase conjugated anti-rabbit 
antibody (Jackson Immunoresearch) and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/
NBT) substrate (Merck KGaA, Darmstadt, Germany). Positive immunolabelling was detected using diaminoben-
zidine (DAB; Sigma). Haematoxylin was used a nuclear counterstain. For immunofluorescence analysis, GFAP 
immunostaining was visualised using goat-anti rabbit iFluora594 (AAT Bioquest, Sunnyvale, USA) and CD44v6 
muris at 105 d after prion infection. (E) The % area of GFAP+CD44v6+ co-immunostaining was significantly 
increased in the hippocampus of mice co-infected with T. muris at 105 d after prion infection when compared to 
mice infected with prions alone. *P < 0.05, Student’s t-test, n = 5–6/group; horizontal bar, median. (F–H) RT–
qPCR analysis revealed a significant increase in expression of the A1 astrocyte-associated genes Gbp2, Psmb8 
and Srgn in the brains of mice with terminal prion disease when compared to uninfected controls. (I–K) RT–
qPCR analysis revealed a significant increase in expression of the A1 astrocyte-associated genes Gbp2, Psmb8 
and Srgn in the brains of mice co-infected with T. muris at 105 d after prion infection. (L–O) RT–qPCR analysis 
suggested no upregulation of the A2 astrocyte-associated genes B3gnt5, Ptx3, Slc10a6 and Tm4sf1 in the brains 
of mice co-infected with T. muris at 105 d after prion infection when compared to uninfected controls. In panels 
F-O, gene expression data were normalized so that the relative mean expression level in uninfected mice was 
1.0. *P < 0.05; **P < 0.01; ***P < 0.001; Student’s t-test, n = 5–6/group; horizontal bar, median.
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immunostaining was detected using biotin-SP AffiniPure Goat anti-rat IgG (H + L; Jackson Immunoresearch). 
IFNGR1 and CD44v6 immunostaining were then visualised using an ABC-HRP kitd (Vector Laboratories) and 
the HRP substrate Tyramide iFluora488 (AAT Bioquest). Sections were mounted in fluorescence mounting 
medium (DAKO) before analysis, and images captured using a confocal laser scanning LSM710 microscope 
with ZEN pro software (Zeiss; https://www.zeiss.com/microscopy/int/products/microscope-software/zen.
html). Sections were stained with haematoxylin and eosin for histopathological assessment of the spongiform 
pathology28.
Figure 7. Astrocytes express high levels of IFN-γ receptor 1 (IFNGR1) in the brain during the pre-clinical 
phase of prion disease. Mice were first injected with ME7 scrapie prions directly into the CNS by IC injection 
and 105 d later they were orally co-infected with a low dose of T. muris infective eggs (~20/mouse). Age 
matched uninfected mice, and mice infected with prions alone or T. muris alone were used as controls. Brains 
were collected during the pre-clinical phase of disease at 140 d after prion infection. (A) Immunofluorescence 
microscopy shows that IFNGR1 (green) was highly expressed in association with GFAP+ astrocytes (red) in 
the brains of mice infected with prions alone, or mice co-infected with T. muris at 105 d after prion infection. 
(B) Detection of IFN-γ in the serum of mice co-infected with prions and T. muris. Each point represents data 
from an individual mouse. **P < 0.01; Student’s t-test, n = 5 mice/group; horizontal bar, median. (C) RT–qPCR 
analysis revealed a significant increase in Ifng expression in the brains of mice co-infected with T. muris at 
105 d after prion infection. Each point represents data from an individual mouse. *P < 0.05; Student’s t-test, 
n = 5–6 mice/group; horizontal bar, median. (D) IHC suggested that IFN-γ was predominantly detected in 
association with astrocytes in the hippocampus of mice co-infected with T. muris at 105 d after prion infection. 
Haematoxylin was used as a nuclear counterstain (blue). (E) Comparison of the magnitude of the IFN-γ+ 
immunostaining in the CA1 region of the hippocampus of mice infected with prions alone or co-infected with 
T. muris at 105 d after prion infection. *P < 0.001, Student’s t-test, n = 5–6/group; horizontal bar, median.
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image analysis. Images were analysed using ImageJ software65 (http://imagej.nih.gov/ij) on coded sections 
blinded to the operator as described previously66,67. Data are presented as the percentage of positively stained 
pixels for each cell marker in the region of interest. The magnitude of the CD44 immunostaining on DAB-stained 
sections was compared as previously described31. Briefly, the optical density (OD) values for CD44 immunostain-
ing were calculated using ImageJ software following H-DAB deconvolution. Mean grey OD values were measured 
from DAB grayscale images (scaled 0–255) and converted using the formula OD = log10 (255/mean grey value). 
Images were typically captured from 5–6 mice/group, and the figure legends provide the sample sizes for each 
parameter analysed.
immunoblot analysis. Homogenates of frozen half brains (10% weight/volume) were prepared in NP-40 
lysis buffer (1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl [pH 7.5]). Samples were 
then treated in the presence/absence of 20 µg/ml proteinase K for 1 h at 37 °C. Following electrophoresis and 
electroblotting onto polyvinylidene difluoride membranes. PrP was detected using mAb 7A1268 as described 
previously69. Supplementary Fig. S1 shows the uncropped immunoblot presented in Fig. 5F.
Rt-qpcR. Half brains were snap-frozen at the temperature of liquid nitrogen, homogenized using Lysing 
Matrix D tubes (MP Biomedicals, Cambridge, UK) and a Ribolyser tissue homogenizer (Bio-Rad Laboratories, 
Figure 8. Detection of CD8α+ cells within the hippocampus during CNS prion disease. Mice were first 
injected with ME7 scrapie prions directly into the CNS by IC injection and 105 d later they were orally co-
infected with a low dose of T. muris infective eggs (~20/mouse). Age matched uninfected mice, and mice 
infected with prions alone or T. muris alone were used as controls. Brains were collected during the pre-
clinical phase of disease at 140 d after prion infection. (A) IHC analysis detected an increased abundance of 
CD8α+ cells (arrows) within the hippocampus of mice co-infected with T. muris at 105 d after prion infection. 
Haematoxylin was used as a nuclear counterstain (blue). (B) A significant increase in the abundance of CD8α+ 
cells was detected within the hippocampus of mice co-infected with T. muris at 105 d after prion infection. Data 
are presented as number of cells/mm2 hippocampus. Each point represents data from an individual mouse. 
**P < 0.01; Student’s t-test, n = 5–6 mice/group; horizontal bar, median. (C) RT–qPCR analysis revealed a 
significant increase in Cd8a expression in the brains of mice co-infected with T. muris at 105 d after prion 
infection. Each point represents data from an individual mouse. **P < 0.01; ***P < 0.001; Student’s t-test, 
n = 5–6 mice/group; horizontal bar, median.
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Watford, UK). Total RNA was extracted using RNABee (AmsBio, Abingdon, UK) and purified using an RNeasy 
Mini kit (Qiagen, Manchester, UK). Genomic DNA was then removed by treatment with RNase-free DNase 
I (Promega, Southampton, UK). First strand cDNA synthesis was performed using 5 µg total RNA and the 
SuperScript III First-Strand Synthesis System for RT-PCR (Life Technologies, Waltham, MA, USA). RT-qPCR 
was then performed using the primers listed in Table 2 and FastStart Universal SYBR Green Master mix (Rox; 
Sigma-Aldrich, Poole, Dorset, UK) on a MX3005P RT-qPCR system (Agilent Technologies LDA UK Ltd, 
Stockport, Cheshire, UK). Cycle threshold values were analysed using MxPro software (Agilent Technologies 
LDA UK Ltd; https://www.agilent.com/en/product/real-time-pcr-(qpcr)/real-time-pcr-(qpcr)-instruments/
mx3000-mx3005p-real-time-pcr-system-software/mxpro-qpcr-software-232751), normalized relative to the ref-
erence gene Rpl19 using the ΔΔCT method and expressed as relative gene expression values compared to the 
uninfected control group.
Statistical analyses. Data are presented as mean ± SEM. Unless indicated otherwise, significant differences 
between samples in different groups were determined by Student’s t-test. In instances where there was evidence of 
non-normality, a Mann-Whitney U test was used. Values of P < 0.05 were accepted as significant.
Data availability
All relevant data are presented within the paper.
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